156 related articles for article (PubMed ID: 2864010)
1. NIH Conference. Alzheimer's disease and Down's syndrome: new insights.
Cutler NR; Heston LL; Davies P; Haxby JV; Schapiro MB
Ann Intern Med; 1985 Oct; 103(4):566-78. PubMed ID: 2864010
[TBL] [Abstract][Full Text] [Related]
2. Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia.
Pietrini P; Dani A; Furey ML; Alexander GE; Freo U; Grady CL; Mentis MJ; Mangot D; Simon EW; Horwitz B; Haxby JV; Schapiro MB
Am J Psychiatry; 1997 Aug; 154(8):1063-9. PubMed ID: 9247390
[TBL] [Abstract][Full Text] [Related]
3. Decline in cerebral glucose utilisation and cognitive function with aging in Down's syndrome.
Schapiro MB; Haxby JV; Grady CL; Duara R; Schlageter NL; White B; Moore A; Sundaram M; Larson SM; Rapoport SI
J Neurol Neurosurg Psychiatry; 1987 Jun; 50(6):766-74. PubMed ID: 2956363
[TBL] [Abstract][Full Text] [Related]
4. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study.
Huang W; Alexander GE; Daly EM; Shetty HU; Krasuski JS; Rapoport SI; Schapiro MB
Am J Psychiatry; 1999 Dec; 156(12):1879-86. PubMed ID: 10588400
[TBL] [Abstract][Full Text] [Related]
5. NIH Conference. Brain imaging: aging and dementia.
Cutler NR; Duara R; Creasey H; Grady CL; Haxby JV; Schapiro MB; Rapoport SI
Ann Intern Med; 1984 Sep; 101(3):355-69. PubMed ID: 6235763
[TBL] [Abstract][Full Text] [Related]
6. Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome.
Cutler NR
Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):309-21. PubMed ID: 2948218
[TBL] [Abstract][Full Text] [Related]
7. Down's syndrome and Alzheimer's dementia: defining an association.
Heston LL
Psychiatr Dev; 1984; 2(4):287-94. PubMed ID: 6241313
[TBL] [Abstract][Full Text] [Related]
8. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.
Hanney M; Prasher V; Williams N; Jones EL; Aarsland D; Corbett A; Lawrence D; Yu LM; Tyrer S; Francis PT; Johnson T; Bullock R; Ballard C;
Lancet; 2012 Feb; 379(9815):528-36. PubMed ID: 22236802
[TBL] [Abstract][Full Text] [Related]
9. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease.
Hof PR; Bouras C; Perl DP; Sparks DL; Mehta N; Morrison JH
Arch Neurol; 1995 Apr; 52(4):379-91. PubMed ID: 7710374
[TBL] [Abstract][Full Text] [Related]
10. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.
Rumble B; Retallack R; Hilbich C; Simms G; Multhaup G; Martins R; Hockey A; Montgomery P; Beyreuther K; Masters CL
N Engl J Med; 1989 Jun; 320(22):1446-52. PubMed ID: 2566117
[TBL] [Abstract][Full Text] [Related]
11. Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down's syndrome: implications for the prodromal phase of Alzheimer's disease.
Krasuski JS; Alexander GE; Horwitz B; Rapoport SI; Schapiro MB
Am J Psychiatry; 2002 Jan; 159(1):74-81. PubMed ID: 11772693
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease in Down's syndrome. A review.
Karlinsky H
J Am Geriatr Soc; 1986 Oct; 34(10):728-34. PubMed ID: 2944942
[TBL] [Abstract][Full Text] [Related]
13. APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome.
Deb S; Braganza J; Norton N; Williams H; Kehoe PG; Williams J; Owen MJ
Br J Psychiatry; 2000 May; 176():468-72. PubMed ID: 10912224
[TBL] [Abstract][Full Text] [Related]
14. Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry.
Teipel SJ; Alexander GE; Schapiro MB; Möller HJ; Rapoport SI; Hampel H
Brain; 2004 Apr; 127(Pt 4):811-24. PubMed ID: 14985261
[TBL] [Abstract][Full Text] [Related]
15. [Down's syndrome and dementia].
Parajuá-Pozo JL; Casis-Arguea S
Rev Neurol; 2000 Jul 16-31; 31(2):126-8. PubMed ID: 10951667
[TBL] [Abstract][Full Text] [Related]
16. Down's syndrome and its association with Alzheimer's disease.
Yatham LN; McHale PA; Kinsella A
Acta Psychiatr Scand; 1988 Jan; 77(1):38-41. PubMed ID: 2964773
[TBL] [Abstract][Full Text] [Related]
17. A four year prospective study of age-related cognitive change in adults with Down's syndrome.
Oliver C; Crayton L; Holland A; Hall S; Bradbury J
Psychol Med; 1998 Nov; 28(6):1365-77. PubMed ID: 9854278
[TBL] [Abstract][Full Text] [Related]
18. Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients.
Blusztajn JK; Lopez Gonzalez-Coviella I; Logue M; Growdon JH; Wurtman RJ
Brain Res; 1990 Dec; 536(1-2):240-4. PubMed ID: 2150771
[TBL] [Abstract][Full Text] [Related]
19. Loss of neurones from cortical and subcortical areas in Down's syndrome patients at middle age. Quantitative comparisons with younger Down's patients and patients with Alzheimer's disease.
Mann DM; Yates PO; Marcyniuk B; Ravindra CR
J Neurol Sci; 1987 Aug; 80(1):79-89. PubMed ID: 2956368
[TBL] [Abstract][Full Text] [Related]
20. Use of electroencephalography to detect Alzheimer's disease in Down's syndrome.
Visser FE; Kuilman M; Oosting J; Overweg J; van Wijk J; van Huffelen AC
Acta Neurol Scand; 1996 Aug; 94(2):97-103. PubMed ID: 8891053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
